
|Articles|May 1, 2005
How to treat refractory OAB using injectable botulinum toxin
No patient has developed urinary retention or elevated post-void residuals following our modified injection technique.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
4
John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC
5






